

Synthesis and Biological Properties of Novel Brefeldin A Analogues

Kai Seehafer,[†] Frank Rominger,[†] Günter Helmchen,^{*,†} Markus Langhans,[‡] David G. Robinson,[‡] Başak Özata,[§] Britta Brügger,[§] Jeroen R. P. M. Strating,[⊥] Frank J. M. van Kuppeveld,[⊥] and Christian D. Klein[#]

[†]Institute of Organic Chemistry, University of Heidelberg, Im Neuenheimer Feld 270, 69120 Heidelberg, Germany


[‡]Department of Plant Cell Biology, Centre for Organismal Studies, University of Heidelberg, Im Neuenheimer Feld 230, 69120 Heidelberg, Germany

[§]Heidelberg University Biochemistry Center, University of Heidelberg, Im Neuenheimer Feld 328, 69120 Heidelberg, Germany

[⊥]Virology Division, Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University, Yalelaan 1, 3584 CL Utrecht, The Netherlands

[#]Institute of Pharmacy and Molecular Biotechnology (IPMB), University of Heidelberg, Im Neuenheimer Feld 364, 69120 Heidelberg, Germany

S Supporting Information



ABSTRACT: New brefeldin A (**1**) analogues were obtained by introducing a variety of substituents at C15. Most of the analogues exhibited significant biological activity. (15*R*)-Trifluoromethyl-nor-brefeldin A (**3**), (15*R*)-vinyl-nor-brefeldin A (**5**), their epimers **4** and **6** as well as (15*S*)-ethyl-nor-brefeldin A (**2**) were prepared from the key building blocks **12** or **24** by Julia–Kocienski olefination with tetrazolyl sulfones and subsequent macrolactonization. The vinyl derivative **5** allowed analogues to be synthesized by hydroboration and Suzuki–Miyaura coupling. The following biological properties were assessed: (a) inhibition of cell growth of human cancer cells (NCI), (b) induction of morphological changes of the Golgi apparatus of plant and mammalian cells, and (c) influence on the replication of the enterovirus CVB3. Furthermore, conformational aspects were studied by X-ray crystal structure analysis and molecular mechanics calculations, including docking of the analogues into the brefeldin A binding site of an Arf1/Sec7-complex.

INTRODUCTION

Brefeldin A (**1**) (Figure 1)¹ is a secondary metabolite of *Ascomycetes* species. It was first isolated in 1958 by Singleton et al.² from *Penicillium decumbens*. Brefeldin A is usually

accompanied by its biogenetic precursor brefeldin C and the oxidation product 7-dehydrobrefeldin A.³ Brefeldin A displays a variety of biological properties, including antifungal,⁴ antiviral,⁵ antineoplastic,⁶ and antimetabolic⁷ activities. Most important, cytostatic activity through apoptosis against numerous human cancer cell lines was found and prompted **1** to be a target for biomedical chemistry.^{8,9}

Another aspect of **1** has led to its use as a reagent of considerable importance for biomedical research. Treatment of eukaryotic cells with **1** induces a reversible morphological disruption, in which the *cis* Golgi apparatus redistributes into the endoplasmic reticulum (ER), an effect that is caused by the breakdown of vesicle-mediated protein transport between both organelles.¹⁰ The underlying event involves binding of **1** to a protein complex that is responsible for vesicle budding. This consists of the small G-protein Arf1 (ADP ribosylation factor 1) and a guanine exchange factor (GEF).^{11,12} The GDP/GTP




Figure 1. Natural brefeldins.

Received: April 25, 2013

Published: June 27, 2013

exchange in Arf1 is catalyzed by Sec7 domain of the GEF. Brefeldin A acts as a noncompetitive inhibitor by binding reversibly at the interface of both proteins. In 2003, Cherfils et al.¹³ and Goldberg et al.¹⁴ published X-ray crystal structures of the Arf1/brefeldin A/Sec7-complex and furnished insights into the binding mode of **1**.

Although **1** exhibits strong cytostatic effects paired with low toxicity in mice ($LD_{50} > 200$ mg/kg, intraperitoneal),⁴ it could not be established as an anticancer drug because of its low bioavailability and poor pharmacokinetics.¹⁵ Subsequent to our previous synthesis of **1** (see below), we decided to synthesize new analogues of **1** that could provide better in vivo stability and solubility, perhaps even possessing improved cytostatic activity when compared with **1**. The new analogues were submitted to the National Cancer Institute (NCI), USA, for screening in their Development Therapeutics Program.¹⁶ Furthermore, the effect on the Golgi apparatus in plant and mammalian cells and replication inhibition of the enterovirus CVB3 were investigated. The analogues were computationally assessed by molecular modeling and docking into the X-ray structure of the Arf1/brefeldin A/Sec7-complex.

A number of analogues of **1** have been reported in conjunction with anticancer investigations. The most successful approach is due to Cushman et al. who developed several classes of prodrugs, which in the end yield **1** itself as active principle.^{17b–e} A second approach was alteration of the structure of **1** itself. Most of the compounds generated in this way showed no or reduced biological activity compared with **1**.¹⁷ There is only one exception, 15-nor-brefeldin A, which was synthesized by our group;^{17h} this compound showed significant activity in tests at the NCI.^{8b} This prompted us to further explore structural variations at C15. It was decided to begin with the new analogues listed in Figure 2.¹




Figure 2. Brefeldin A analogues.

Our syntheses are based on a strategy, see Figure 3, which we have recently reported.^{17g} Key intermediate is the aldehyde **A** that is derived from **1** by saponification and oxidative cleavage of the lower side chain with OsO₄/periodate. Aldehyde **A** can be combined with various tetrazolyl sulfones **B** in a convergent and stereoselective manner by Julia–Kocienski olefination. A subsequent macrolactonization usually proceeds with good yield. A particularly versatile early target was (15*R*)-vinyl-nor-brefeldin A (**5**), from which further derivatives could be efficiently generated in a late stage of their synthesis via addition reactions and Suzuki coupling.

RESULTS AND DISCUSSION

Synthesis of (15*S*)-Ethyl-nor-brefeldin A (2**).** The synthesis of the requisite side chain precursor, the tetrazolyl sulfone **11**, is described in Scheme 1. The aldehyde **7**, accessible in two steps from commercially available 1,5-pentanediol,¹⁸ was




Figure 3. Retrosynthetic analysis (Σ : protecting group).


converted into the enantiomerically enriched alcohol **8** by asymmetric addition¹⁹ of diethylzinc using (–)-DBNE²⁰ as chiral ligand. At a reaction temperature of 0 °C, **8** was obtained in 88% yield with 87% ee. TBS-deprotection followed by Mitsunobu reaction with 1-phenyl-1*H*-tetrazole-5-thiol and protection of the secondary hydroxyl group gave the sulfide **10**, which furnished the tetrazolyl sulfone **11** by Mo(VI)-catalyzed oxidation.²¹

The Julia–Kocienski olefination of tetrazolyl sulfone **11** and the from **1** derived aldehyde **12**^{17g,22} proceeded with essentially complete stereocontrol to give the *E*-olefin **13** in 73% yield (Scheme 2).²³ Selective deprotection gave the hydroxy ester **14**, which was saponified to the corresponding hydroxy acid, which was then subjected to macrolactonization under Yamaguchi conditions, yielding **15** in excellent yield of 88%.²⁴ MEM-deprotection with concentrated HBr^{17h,25} and purification by recrystallization furnished **2** in 75% yield.


Synthesis of (15*R*)- and (15*S*)-Trifluoromethyl-nor-brefeldin A (3**, **4**).** Considering that selective substitution of hydrogen by fluorine can affect both pharmacokinetics and pharmacodynamics of a bioactive compound dramatically,²⁶ we synthesized an analogue of **1** with the 15-CH₃ group exchanged for a CF₃ group (Scheme 3). Using our general strategy, we first prepared the tetrazolyl sulfone **21**, starting with the commercially available diol **16**. A Mitsunobu reaction followed by a Swern oxidation yielded the aldehyde **18**. Reaction of **18** with the Ruppert–Prakash reagent and a catalytic amount of TBAF furnished the racemic alcohol **19**.²⁷ Subsequent oxidation of the sulfide **19** and TES-protection of the secondary alcohol **20** provided the racemic building block **21**.

The synthesis of the second building block, **24**, is described in Scheme 4. We decided to use TBS rather than MEM as protecting group in order to simplify workup and NMR spectra of the synthetic intermediates. First, TBS-protection of the hydroxyl groups of **1** to give **22** was carried out as described by Cushman and co-workers.^{17c} Subsequent saponification and esterification with diazomethane gave the hydroxy ester **23**. This was subjected to selective oxidative cleavage with OsO₄/periodate to furnish the aldehyde **24** in excellent yield.


The building blocks **21** and **24** were combined by a Julia–Kocienski olefination under Barbier-type conditions to provide compound **25** (Scheme 5). Selective TES-deprotection in the presence of the OTBS groups was accomplished with the triethylamine trihydrofluoride complex to yield hydroxy ester **26** in 90% yield. Saponification and macrolactonization under

Scheme 1^a


^aReagents and conditions: (a) Et_2Zn , $(-)\text{-DBNE}$, toluene, 0°C , 24 h, 87% ee; (b) HCl , THF, rt, 20 min; (c) (i) PPh_3 , DEAD, 1-phenyl-1*H*-tetrazole-5-thiol, THF, 0°C to rt, 16 h, (ii) TBS-Cl , imidazole, DMAP, CH_2Cl_2 , 0°C to rt, 3 h; (d) $(\text{NH}_4)_6\text{Mo}_7\text{O}_{24}\cdot 4\text{H}_2\text{O}$, H_2O_2 , EtOH, rt, 16 h.

Scheme 2^a

^aReagents and conditions: (a) compound 11, KHMDS, 1,2-dimethoxyethane, -78°C to rt, 18 h; (b) HCl , THF, rt, 2 h; (c) (i) LiOH , THF/ H_2O , rt, 2 h, (ii) 2,4,6-trichlorobenzoylchloride, NEt_3 , THF, rt, 1.5 h, (iii) DMAP, toluene, reflux, 5 h; (d) (i) conc HBr , THF, rt, 1.5 h, (ii) recrystallization.

Scheme 3^a


^aReagents and conditions: (a) PPh_3 , DIAD, 1-phenyl-1*H*-tetrazole-5-thiol, THF, 0°C to rt, 16 h; (b) $(\text{COCl})_2$, DMSO, NEt_3 , CH_2Cl_2 , -78°C , 45 min; (c) $\text{CF}_3\text{-SiMe}_3$, TBAF, THF, 0°C to rt, 1 h; (d) $(\text{NH}_4)_6\text{Mo}_7\text{O}_{24}\cdot 4\text{H}_2\text{O}$, H_2O_2 , EtOH, rt, 16 h; (e) TES-Cl, imidazole, DMAP, CH_2Cl_2 , rt, 20 min.

Scheme 4^a

^aReagents and conditions: (a) TBS-Cl , imidazole, DMAP, CH_2Cl_2 , 40°C , 20 h; (b) (i) KOH , MeOH, 40°C , 30 min, (ii) CH_2N_2 , EtOAc, rt; (c) (i) $\text{K}_2\text{OsO}_4\cdot 2\text{H}_2\text{O}$, NMO, acetone/ H_2O , rt, 3 h, (ii) NaIO_4 , THF/ H_2O , rt, 2 h.

Yamaguchi conditions²⁴ furnished the epimers 27 and 28, which could be separated by HPLC. Standard deprotection gave the target compounds 3 and 4, respectively. The relative configuration of the epimers at C15 could be assigned by a X-ray crystal structure analysis of 3 (Figure 4). Structural assignment of C15-epimers is also generally possible by ^1H NMR because for all cyclic compounds there are characteristic differences in chemical shifts (see below).

Synthesis of (15*R*)- and (15*S*)-Vinyl-nor-brefeldin A (5, 6). (15*S*)-Ethyl-nor-brefeldin A (2) displayed promising anticancer activity in tests at NCI (see below). Thus, exploration of the corresponding vinyl derivative, (15*R*)-vinyl-nor-brefeldin A (4), was of interest; this compound was also useful as relay for late stage syntheses of further analogues of 1. The synthesis of 4 relied on a new procedure for enantioselective synthesis of branched allyl alcohols, an iridium-catalyzed allylic hydroxylation, developed by our

Scheme 5^a

^aReagents and conditions: (a) KHMDS, 1,2-dimethoxyethane, -78°C to rt, 16 h; (b) $\text{NEt}_3\cdot 3\text{HF}$, CH_3CN , rt, 30 min; (c) (i) NaOH , THF/MeOH , 60°C , 1 h, (ii) 2,4,6-trichlorobenzoylchloride, NEt_3 , THF , rt, 2 h, (iii) DMAP, toluene, reflux to rt, 16 h, (iv) separation of 27 and 28 by HPLC; (d) $\text{NEt}_3\cdot 3\text{HF}$, CH_3CN , 60°C , 18 h.





Figure 4. X-ray crystal structure of compound 3.

group.²⁸ We decided to apply this procedure in a catalyst-controlled diastereoselective manner to the brefeldin A-derived intermediate 33 (Scheme 7). The side-chain precursor of this compound was prepared as follows (Scheme 6). Aldehyde 18 was subjected to a HWE olefination to give the enoate 29, which was reduced to the allylic alcohol 30. Subsequent carbonate formation and oxidation of the sulfide 31 provided the tetrazolyl sulfone 32 in excellent overall yield.

Julia-Kocienski olefination of 24 with 32 under Barbier-type conditions yielded the methyl carbonate 33 *E*-selectively in 84% yield. Next the aforementioned asymmetric iridium-catalyzed allylic hydroxylation was applied, using (π -allyl)Ir-complexes C3 (Figure 5) or *ent*-C3 as catalysts;²⁸ alcohols 34 and 35 were generated in high yield and diastereoselectivity of 95:5 and 5:95, respectively. Saponification followed by macrolactonization gave the diastereoisomers 36 and 37, which were subjected to the standard deprotection already described to give the diastereomeric target compounds 5 and its epimer 6, respectively.


Scheme 6^a

^aReagents and conditions: (a) NaH , $(\text{EtO})_2\text{P}(\text{O})\text{CH}_2\text{O}_2\text{Et}$, THF , -78°C to rt, 14 h; (b) DIBAL-H, THF , -78°C , 2.5 h; (c) ClCO_2Me , pyridine, CH_2Cl_2 , 0°C to rt, 1 h; (d) $(\text{NH}_4)_6\text{Mo}_7\text{O}_{24}\cdot 4\text{H}_2\text{O}$, H_2O_2 , EtOH , 0°C to rt, 16 h.


15-(2-Arylethyl)-nor-brefeldin A Derivatives 39 via Suzuki-Miyaura Coupling. Both (15*S*)-ethyl-nor-brefeldin A (2) and (15*R*)-vinyl-nor-brefeldin A (5) showed good cytostatic activity in the NCI assessment (see below), it was therefore of interest to further vary the substituent at C15. First, aryl groups were introduced by Suzuki–Miyaura coupling between di-TBS-protected (15*R*)-vinyl-nor-brefeldin A (36) and aryl halides. The target compounds and yields are listed in Table 1. The crucial step of these syntheses was the preparation of a suitable borane by hydroboration of 36, selectively at the vinyl group rather than double bond $\Delta^{10,11}$. This problem was solved by reaction of 36 with the bulky borane 9-BBN at 70°C for 5 min; the subsequent Suzuki–Miyaura coupling gave 38a–f in moderate to good overall yield. Deprotection under our standard conditions gave the target compounds 39a–f.

nor-Brefeldin A Derivatives with Polar Substituents at C15. The di-TBS-protected (15*R*)-vinyl-nor-brefeldin A (36) allowed a broad spectrum of compounds considerably more polar than the previous ones to be prepared. The synthesis of the diastereomeric diols 42 and 43 was carried out first (Scheme 8) in order to obtain compounds more soluble in water than 1. Asymmetric dihydroxylation (AD) reaction²⁹ using an osmium complex of a bulky cinchona alkaloid was expected to favor reaction at the vinyl group. With Sharpless' commercially available AD-mix- β (containing $(\text{DHQD})_2\text{PHAL}$ as chiral ligand),³⁰ diastereoisomers 40 and 41 were obtained in overall yield of 44% in a ratio of ca. 3:1, respectively. The diastereoisomers were separated by HPLC. Deprotection and recrystallization gave pure diols 42 and 43.

The diol 40 was used to access (15*R*)-(hydroxymethyl)-nor-brefeldin A (46) (Scheme 9). The aldehyde 44 is prone to

Scheme 7^a

^aReagents and conditions: (a) KHMDS, 1,2-dimethoxyethane, -78°C to rt, 18 h; (b) C3 (Figure 5) or *ent*-C3, KHCO_3 , DMF/ H_2O , rt, 3 h; (c) (i) NaOH, THF/MeOH, 60°C , (ii) 2,4,6-trichlorobenzoylchloride, NEt_3 , THF, rt, 2.5 h, (iii) DMAP, toluene, reflux; (d) $\text{NEt}_3\cdot 3\text{HF}$, CH_3CN , 60°C , 15 h.


Figure 5. (π -Allyl)Ir-complex C3.

epimerization. This could be suppressed by carrying out periodate cleavage with **40** in a phosphate buffer system. The aldehyde was reduced with NaBH_4 to give **45** cleanly after 2 min and in 88% yield. A short reaction time is necessary in order to prevent intramolecular transesterification (see below). Finally, standard TBS-deprotection and recrystallization gave triol **46** in excellent yield. The homologous alcohol **48** was prepared from the vinyl derivative **36** by hydroboration with 9-BBN and oxidation, followed by standard desilylation (Scheme 10).

With alcohol **47** in hand, it appeared logical to generate ethers such as **51** and **52** (Scheme 11). This turned out to be more difficult than anticipated because of facile intramolecular transesterification (see below). After some experimentation, the following procedures gave good results. The methyl ether **49** was obtained by treating a solution of **47** in methyl iodide with silver(I)-oxide, according to a procedure described by Greene et al.³¹ for a total synthesis of **1**. The benzyl ether **50** was similarly prepared in good yield by treating **47** in BnBr as solvent with a catalytic amounts of TBAI. Standard deprotection gave brefeldin A ether analogues **51** and **52** in high yield.

The intramolecular transesterification mentioned above occurred upon attempted etherification of alcohol **47** with NaH and BnBr, which gave only a very low yield of the benzyl ether but mainly gave rise to the ring expanded secondary alcohol **53**, which was obtained in almost quantitative yield after optimization of the reaction conditions (Scheme 12). Standard deprotection gave the triol **54**, which was characterized by X-ray crystal structure analysis (Figure 10C).


Given di-TBS-protected compound **36**, it was straightforward to synthesize 15-acetyl-nor-brefeldin A (**56**) via a Wacker

Table 1. Preparation of Aryl Derivatives **38a–f** and **39a–f** via Suzuki–Miyaura-Type Coupling and Deprotection^a


entry	Ar	yield (%) of 38	yield (%) of 39
1		a 59	85
2		b 52	93
3		c 64	71
4		d 41	84
5		e 68	90 ^b
6		f 66	96

^aReagents and conditions: (a) (i) 9-BBN, THF, 70°C , 5 min, (ii) Ar-X, $\text{Pd}(\text{dppf})\text{Cl}_2$, Ph_3As , Cs_2CO_3 , DMF/ H_2O , rt or 50°C ; (b) (i) $\text{NEt}_3\cdot 3\text{HF}$, CH_3CN , 60°C , 15 h, (ii) recrystallization. ^bReagents and conditions: (i) HCl, MeOH, 40°C , 2 h, (ii) recrystallization.


oxidation³² (Scheme 13), anticipating that reaction at the secondary atom of the vinyl group would be favored. The Wacker oxidation was carried out with palladium(II)-chloride, copper(I)-chloride and oxygen to give methyl ketone **55** in 41% yield after 23 h at rt. In addition, the corresponding aldehyde was isolated in 17% yield. Deprotection of **55** with triethylamine trihydrofluoride gave the methyl ketone **56** in 87% yield.

Scheme 8^a

^aReagents and conditions: (a) (i) AD-Mix- β , MeSO₂NH₂, *t*-BuOH/H₂O, rt, 16 h, (ii) separation of **40** and **41** by HPLC; (b) with **40**, (i) NEt₃·3HF, CH₃CN, 60 °C, 17 h, (ii) recrystallization; with **41**, (i) HCl, THF, 40 °C, 2 h, (ii) recrystallization.

Scheme 9^a


^aReagents and conditions: (a) NaIO₄, THF/0.25 M NaH₂PO₄/Na₂HPO₄ (pH 7), rt, 1 h; (b) NaBH₄, THF/H₂O, rt, 2 min; (c) (i) NEt₃·3HF, CH₃CN, 60 °C, 15 h, (ii) recrystallization.

Scheme 10^a


^aReagents and conditions: (a) (i) 9-BBN, THF, 70 °C, 5 min, (ii) NaOH, H₂O₂, 0 °C, 20 min; (b) (i) NEt₃·3HF, CH₃CN, 60 °C, 15 h, (ii) recrystallization.

The analogues derived by Suzuki–Miyaura coupling showed high biological activity. It appeared of interest to add an amide group to the aryl moiety in order to increase polarity and hydrogen bonding capacity (Scheme 14). Accordingly the amine **38d** was acylated with acetyl chloride to furnish amide **57** after 5 min in 89% yield. Standard deprotection gave the amide **58** in good yield.


Biological Properties of the Brefeldin A Analogues. Anticancer Activity Tested at NCI. Except for **39f**, the new analogues of **1** were submitted to the National Cancer Institute (NCI, Maryland, USA) of the U.S. National Institutes of Health for evaluation of their anticancer activity within the Developmental Therapeutics Program (DTP). The substances were first applied to 60 human cancer cell lines including lung, colon, CNS, ovarian, renal, prostate, and breast cancer cell lines

Scheme 11^a


^aReagents and conditions: (a) Ag₂O, MeI, rt, 7.5 h or Ag₂O, TBAI, BnBr, rt, 7 h; (b) (i) NEt₃·3HF, CH₃CN, 60 °C, 15 h, (ii) recrystallization.

Scheme 12^a

^aReagents and conditions: (a) NaH, THF, 0 °C, 30 min; (b) (i) NEt₃·3HF, CH₃CN, 60 °C, 15 h, (ii) recrystallization.


Scheme 13^a










^aReagents and conditions: (a) PdCl₂, CuCl, O₂, *N,N*-dimethylacetamide/H₂O, rt, 23 h; (b) (i) NEt₃·3HF, CH₃CN, 60 °C, 15 h, (ii) recrystallization.

Scheme 14^a.

^aReagents and conditions: (a) MeCOCl, NEt₃, THF, 0 °C, 5 min; (b) (i) NEt₃·3HF, CH₃CN/MeOH, 60 °C, 15 h, (ii) recrystallization.

Table 2. Cytostatic/Cytotoxic Activity of the Active Analogues and 1 against Human Cancer Cell Lines



compound ^a	15-R	NSC ^b	GI ₅₀ (nM) ^c	TGI (μM) ^c	LC ₅₀ (μM) ^c
1	CH ₃	NSC56310	20.6	3.48	52.6
nor-brefeldin A ^{17h}	H	NSC746708	631.0 ^d	20.9 ^d	69.2 ^d
2	CH ₂ CH ₃	NCS755268	44.6	5.82	35.8
3	CF ₃	NSC763494	321.0	5.49	48.2
5		NSC755269	31.9	4.91	39.0
6		NSC758119	630.5	17.75	66.3
39a		NSC757947	29.9	2.04	40.0
39b		NSC761150	73.9	2.28	25.1
39c		NSC761151	261.5	7.61	63.9
39d		NSC762147	34.3	2.68	56.3
39e		NSC762150	212.0	5.97	66.2
46		NSC761154	2570 ^d	38.00 ^d	85.1 ^d
48		NSC757946	178.0	7.69	47.6
51		NSC757948	90.2	5.78	42.3
52		NSC757949	80.9	5.05	35.5
56		NSC761152	593.5	13.35	61.7
58		NSC762149	152.0	5.70	51.6

^aCompounds that were only assessed by a 1-dose test are not included. ^bInternal ID number of the NCI. ^cMean values of two different 5-dose tests. ^dValues of one 5-dose test.

as well as leukemia and melanoma cells at a high concentration of 10 μM (1-dose test). Compounds displaying significant activity were then tested at five different concentrations on the same cells (5-dose test), establishing the parameters GI₅₀ (growth inhibition 50%; concentration of drug at which cell proliferation is inhibited by 50%), TGI (total growth inhibition;

concentration of drug at which cell proliferation is inhibited by 100%), and LC₅₀ (lethal dose 50%; concentration of drug at which 50% of cell population is killed).¹⁶ Table 2 provides the results of the five-dose tests as averages of all cell lines. Detailed information, for instance the activities for each cell line, will also soon be published in the database of the NCI.^{8b} As an example,

the five-dose test results for the highly active analogue **5** are given in the Supporting Information.

The analogues **2**, **5**, **39a**, and **39d** are highly active, reducing cell growth of colon cancer cells, renal cancer cells and melanoma cells at a comparable concentration as **1** does. Moreover, these derivatives display a stronger anticancer effect than **1** on breast cancer cell lines. Slightly lower activities were determined for the naphthyl-derivative **39b**, **51**, and **52**. (15*R*)-Trifluoromethyl-nor-brefeldin A (**3**), **39c**, **39e**, **48**, and **58** are less active than **1**, requiring a 10-fold higher concentration to achieve the same growth inhibition as **1**. Compounds **6**, **46**, **56**, and nor-brefeldin A,^{17h} previously synthesized in our group, cause inhibition only at higher concentrations. Almost inactive are the compound **4**, the tetrols **42** and **43**, and the ring expanded analogue **54** that were not selected for the five-dose screen and are not listed in the table. The same is also true for the (6*R*)-hydroxybrefeldin A, (7*S*)-aminobrefeldin C, and the lactam analogue of **1** previously synthesized in our laboratory.^{17g,33}

Effects of Brefeldin A Analogues on Plant Cells. As previously carried out,³⁴ we have screened the analogues for brefeldin A activity on tobacco leaf protoplasts transiently expressing the fluorescent *cis* Golgi marker protein Man1-RFP, and on root cells of an *Arabidopsis* line stably expressing the *trans* Golgi marker ST-YFP and the *trans* Golgi network (TGN) marker VHAA1-RFP. As seen in Figure 6, under control conditions the Golgi marker in protoplasts assumes a punctate appearance corresponding to the hundreds of Golgi stacks normally present in a plant cell (Figure 6A). Addition of **1** for




Figure 6. Effects of **1** (**B**) and analogues **39a**, **39c**, **58**, and **39e** (**C–F**) on tobacco mesophyll protoplasts transiently expressing the *cis* Golgi marker Man1-RFP. Protoplasts were treated with 90 μ M of **1** and analogues of **1** for 30 min before observing in the CLSM. The control (**A**) shows the normal Golgi distribution in plant cells. Magnification bars (**A–F**) = 5 μ m.

30 min results in a fusion of the Golgi with the ER with the Golgi marker then becoming distributed throughout the ER network and nuclear envelope (Figure 6B). The same phenotype was observed after application of the analogues **39a**, **39c**, **58** and **39e** (Figure 6C–F). Similarly, the analogues **2** and **5** when applied to *Arabidopsis* roots elicited the same phenotype as **1** itself, namely the formation of a “brefeldin A-compartment” with large central core of TGN elements and surrounding Golgi stacks (compare **A** with **B–D** in Figure 7).




Figure 7. Effects of **1** (**B**) and brefeldin A analogues **2** (**C**) and **5** (**D**) on *Arabidopsis* root cells stably expressing the Golgi marker ST-YFP and the TGN marker VHAA1-RFP. Roots were treated with 90 μ M of **1** (**B**) and analogues of **1** (**C,D**) for 30 min before observing in the CLSM. The control (**A**) shows the normal Golgi and TGN distribution in plant cells. Magnification bars (**A–D**) = 5 μ m.

Golgi Disruption in Mammalian Cells. To study Golgi disassembly, HeLa cells were incubated for either 30 or 60 min in the presence of the various drugs. Cells were fixed and processed as described in the Experimental Section. Visualization of *cis* Golgi structures was performed using an anti-GM130 antibody. Reassembly studies were performed after 60 min incubation in the presence of **1** or the indicated analogues, followed by an additional 2 h incubation in medium in the absence of drug. Immunolabeled cells were analyzed by confocal microscopy (Figure 8). While all drugs tested induced Golgi disassembly, only after removal of substance **39e** was a Golgi reassembly comparable to **1** observed. Substance **39a** and **39b** allowed partial recovery of Golgi structure, whereas the analogue **5** induced an irreversible Golgi disruption.

Replication Inhibition of the Enterovirus CVB3. Brefeldin A is a well-known inhibitor of the replication of enteroviruses.^{35,36} Enteroviruses are a large group (>250 members) of viruses, which includes among others poliovirus (the causative agent of poliomyelitis), the rhinoviruses (common cold), and the coxsackieviruses (the main cause of viral myocarditis, pancreatitis, and meningitis). Enteroviruses have a single-stranded RNA genome of positive-orientation, which is replicated on reorganized intracellular membranes by assemblies of viral proteins and hijacked cellular proteins.^{37,38} These host proteins include GBF1,^{39–41} which is inhibited by **1**.^{42,43} To test whether our analogues could also inhibit enterovirus replication, we infected cells with a recombinant coxsackievirus B3 (CVB3) that carried a *Renilla* luciferase gene⁴¹ and




Figure 8. HeLa cells were treated with **1** and the analogues **5** and **39e**. Control cells were incubated in medium. After 60 min incubation of cells in the presence of drug, wash-out experiments were performed after removal of the drug by incubating cells for additional 2 h in medium without drug. Cells were immunolabeled with an anti-GM130 antibody and visualized by confocal microscopy.

subsequently incubated the cells for 7 h in the presence or absence of compound to allow the replication of the viral genome. Upon viral genome replication, luciferase activity increases exponentially and can be readily assessed as a measure of viral genome replication. At a concentration of $\sim 5 \mu\text{M}$, **1** normally causes a nearly complete inhibition of replication. To assess the potency of the compounds, we tested this concentration and a 10-fold higher and lower concentration.

As shown in Figure 9, we found that at 5 and 50 μM all tested compounds inhibited replication of CVB3 to about the same extent as **1**. Only at 0.5 μM , several analogues inhibited replication to about one log value less than **1** did, except for the analogue **5**, which was about one log more potent than **1**, and **39e**, which inhibited virus replication clearly less potent than **1** at both 5 and 0.5 μM . This effect on replication was specific and not due to toxicity of the compounds, since at the tested concentrations none of the compounds cause a notable reduction of cell viability (see Supporting Information). Thus, all analogues of **1** tested have retained the capability to inhibit the replication of enteroviruses. The vinyl derivative **5** also shows particularly strong inhibition of cancer cell growth, whereas **39e** displayed a less strong inhibition of cancer cell growth.

Crystal Structures and NMR Spectra of the Brefeldin A Analogues.

X-ray crystal structures of the analogues **2**, **3**, **5**, **6**, **39a**, **42**, **48**, and **54** were determined in order to compare the conformations of the new analogues with that of **1**. Superimpositions of the structures of a representative set of analogues with the structure of **1** are displayed in Figure 10. For derivative **5**, a very close fit is apparent (Figure 10A), with a root-mean-square deviation (rmsd) of only 0.03 Å (based on the core atoms). This is also true for the analogues **2**, **3**, **39a**, **42**, and **48**, which only differ from **5** in the substituent at C15. However, by changing the configuration at C15, as in analogue **6**, both the conformation of the five- and the 13-membered ring are strongly affected, leading to a much increased rmsd of 0.57 Å (Figure 10B). The major change is seen for the upper, polar side chain of the 13-membered ring. While these derivatives show the enoate moiety ($\text{O}=\text{C}-\text{C}=\text{C}$) in the natural




Figure 9. HeLa R19 cells were infected with RLuc-CVB3 virus as described in the Experimental Section procedures and treated with the analogues, **1** or a corresponding dilution of DMSO as a negative control for 7 h. Cells were lysed and the *Renilla* luciferase activity as a measure of virus replication was measured. Luciferase activity is expressed relative to the control with the same DMSO dilution and shown on a logarithmic scale. Triplicates measurements are shown as means $\pm$ SEM. Like **1**, at the concentrations used, the analogues do not considerably affect the viability of the cells within the time frame of the experiment (see Supporting Information).




Figure 10. Superpositions of the X-ray crystal structures of different brefeldin A analogues (purple) and **1** (gray). (A) Analogue **5**; (B) analogue **6**; (C) analogue **54**.

occurring *s-trans* conformation, conformation with respect to the bonds C3–C4 and C4–C5 differ considerably. The ring expanded compound **54** (Figure 10C) is conformationally similar to **1** around the five-membered ring, while the conformation of the macrocycle differs considerably.

The differences in the conformational situation of the C15-epimers **3** and **4** as well as **5** and **6** are reflected by their ^1H NMR spectra (see Supporting Information). Thus, for the analogues **3** and **5**, possessing the same configuration as **1**, one of the diastereotopic protons at C-13 resonates at <1 ppm and the olefinic proton at C-3 at 7.5 ppm, while for the epimers **4** and **6** the signal of the 13-H is found at 1.4–1.5 ppm and that of the 3-H at 6.8 ppm.

Molecular Modeling and Protein–Ligand Docking with the Brefeldin A Analogues. We also investigated the structures of all new analogues by molecular modeling, using the MacroModel⁴⁴ software and a procedure developed by Still et al. that is based on the mmffs force field and a Monte Carlo Multiple Minimum (MCM) search; they applied this procedure to 7-dehydro-brefeldin A for validation.⁴⁵

As observed in our previous investigation,^{17g} the calculated minimal energy structures and the X-ray crystal structures of the analogues are superposable for the macrocyclic moiety, while conformers differ for the cyclopentane ring. For this, the conformer with an equatorial 7-OH group is generally preferred in the calculations, while in all crystal structures determined by us the conformer with an axial 7-OH group pertains. However, the energy difference between these conformers is small, calculated as only 0.79 kJ/mol for **1**. Inspection of the crystal structure of **1** indicates that hydrogen bonding in the crystal is responsible for the preference of the axial conformer (cf.^{17g}). The conformer with an equatorial 7-OH group was found in the crystal structure of the Arf1/brefeldin A/Sec7-complex.

Docking experiments were carried out with the calculated conformers of lowest energy, using GOLD 5.1⁴⁶ with ChemPLP as scoring function and the UCSF Chimera package⁴⁷ for visualization. The X-ray crystal structure of the

Arf1/brefeldin A/Sec7-complex from the PDB⁴⁸ (ID code: 1RE0¹⁴) was prepared for docking using the additional programs of the GOLD package. Thus, the ligand **1** was removed from the binding pocket, a new binding pocket was defined (CZ of TYR81, radius 10 Å), and different rotamers were allowed for four amino acids (ARG19, TRP66, TYR81, VAL270), which are thought to be important with regard to the interactions with the substituents at C15 of the analogues. Furthermore, water molecules in this region and in the vicinity of the binding site were defined as flexible. Otherwise, the default settings of the GOLD package were used.

The analogues **2** and **5** scored similar docking scores as **1**. All the other analogues with the natural configuration at C15 achieved much higher docking scores. These analogues were docked in a position and orientation (pose) that resembles the pose of **1** in the X-ray structure. As example, docking results for (15*R*)(2-phenylethyl)-nor-brefeldin A (**39a**) are described in Figure 11 (left); the first three docked poses are superposed.




Figure 11. Close-up view of the X-ray crystal complex (PDB ID code: 1RE0) consisting of **1** (purple) in the binding pocket between Arf1 (green ribbon) and Sec7 (yellow ribbon). Left, overlay of the first three docked poses of **39a** (turquoise); right, overlay of the docked pose of **6** (turquoise).

Three conformers with different orientation of the aryl group are accepted, implicating that bulky residues at C15 are well tolerated.

The compounds with the non-natural configuration at C15, **4**, **6**, and the ring expanded **54** gave much lower docking scores than **1**. These compounds show an anomalous pose, as illustrated by analogue **6** (Figure 11, right).

Relationship of Structure and Cytostatic Activity. Several classes of the analogues of **1** can be distinguished (cf. Table 2).

The analogues **2**, **5**, **39a**, and **39b**, carrying a nonpolar substituent at C15, are highly active compounds, provide high docking scores, and also show a conformation and docked pose similar to **1**. Even bulky residues at C15, i.e., the 1-naphthyl moiety in **39b**, are well accepted.

The compounds **4** and **6**, with the non-natural configuration at C15, and the ring expanded compound **54** are nearly inactive. The calculated low energy conformers of these compounds differ considerably from that of **1**, and they possess a low docking score and abnormal docking pose.

The alcohols **42** and **43** with the highly polar 1,2-dihydroxyethyl substituent at C15 display extremely low activity. Very low activity was also obtained for **46**, carrying a hydroxymethyl group at C15, and low activity was found for **48**, and **56**, with a 2-hydroxyethyl- and an acetyl group, respectively, at C15. All these analogues provide high docking scores and conformational similarity to **1**. Accordingly, conformational similarity to **1** appears as necessary but not as sufficient condition for cytostatic activity.

Compounds with a large apolar substituent containing a small polar moiety, **39c** with a 7-quinolyl and **39d** with a 4-aminophenyl group, command interest. While the former is almost inactive, the latter is highly active. However, the *N*-acetyl derivative **58**, derived from **39d**, is inactive.

CONCLUSIONS

We have synthesized (15*R*)-trifluoromethyl-nor-brefeldin A (**3**), (15*R*)-vinyl-nor-brefeldin A (**5**), their C15-epimers **4** and **6**, as well as (15*S*)-ethyl-nor-brefeldin A (**2**). The vinyl derivative **5** allowed further analogues to be generated efficiently by hydroboration/Suzuki–Miyaura coupling and other addition reactions. Conformational analyses were carried out by X-ray crystal structure determinations and molecular mechanics calculations. For all brefeldin A analogues, computational docking into the brefeldin A (**1**) binding site of the Arf1/Sec7 complex was conducted.

The analogues were tested for their cytostatic effects in human cancer cells. Activity was found for nearly all compounds. High activity was obtained for **2** and **5** as well as **39a** and **39b**, bearing a phenyl and a 4-aminophenyl group at C15, respectively. In addition, the ability of inducing morphological changes in the Golgi apparatus in plant and mammalian cells as well as inhibition of the replication of the enterovirus CVB3 in HeLa cells was investigated. In most cases, effects similar to those of **1** were found; however, the analogue **5** displayed 10-fold higher activity than **1** against the enterovirus CVB3.

EXPERIMENTAL SECTION

Details on the synthesis of all compounds are given in the Supporting Information. The purity of all tested compounds was determined by analytical HPLC to be >95%.

The Effects of Brefeldin A Analogues on Plant Cells. Plants of *Arabidopsis thaliana* stably transformed with VHAA1-RFP/N-ST-YFP⁴⁹ were grown from surface-sterilized seeds in half-strength Murashige and Skoog (MS) medium⁵⁰ with 1% (w/v) sucrose in a controlled climate room at 22 °C with a 16 h day length. Transient expression in protoplasts of *Nicotiana tabacum* cv. Petit Havana was done exactly as described in Langhans et al. in 2011.³⁴ Drug Treatment: Control experiments were performed with a standard concentration of 90 μM **1** (stock solution 5 mg/mL **1** in DMSO) in half MS media for 30 min or without **1** in half MS media and then observed under the microscope. In following experiments plants were treated 30 min with 90 μM of different brefeldin A analogues as described before. Analogues were dissolved in DMSO. Confocal microscopy: 80 μL protoplast solution of *N. tabacum* and *A. thaliana* roots were transferred to slides as previously described in Langhans et al. in 2011.³⁴ Cells or plant material were observed under a Zeiss Axiovert LSM510 Meta microscope using a CApochromat 63/1.2 W corr water immersion objective for protoplasts and roots. Special settings were designed for observing single or double expression with different XFPconstructs. Fluorescence was detected by the Meta-detector using main beam splitters HFT 488/543. The following fluorophores (excited and emitted by frame switching in the single or multitracking mode) were used: YFP (488 nm/529–550 nm) and RFP (543 nm/593–625 nm). Pinholes were adjusted to 1 Airy Unit for each wavelength. Postacquisition image processing was performed using the Zeiss LSM 510 image Browser (4.2.0.121), CorelDrawX4 (14.0.0.567) and ImageJ (1.46o).

Golgi Disruption in Mammalian Cells. As previously described,⁵¹ HeLa cells were cultivated in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum, 100 units/mL penicillin, 100 μg/mL streptomycin, and 2 mM L-glutamine. **1** and its analogues were added to cells at a final concentration of 5 μM. Cells were incubated at 37 °C for 30 or 60 min and then fixed

with 4% paraformaldehyde in phosphate buffered saline (PBS) for 20 min at rt. Following a 20 min incubation in 50 mM ammonium chloride at rt, cells were permeabilized for 5 min at rt with 0.5% Triton-X-100 in PBS. Blocking was performed for 15 min at rt in 5% BSA in PBS. Cells were then incubated with an anti-GM130 antibody (BD Transduction Laboratories) for 30 min at rt. As secondary antibody Alexa Flour 546-coupled-goat-antimouse (Invitrogen, cat. no. A11030) was used. After each step, cells were washed twice for 5 min in PBS. Cells were mounted in Prolong Gold antifade mounting reagent (Invitrogen) and stored at 4 °C. Immunolabeled cells were protected against light. Immunofluorescence was then analyzed with a Zeiss LSM510 confocal microscope. A Plan-Apochromat 63×/1.4 Oil DIC objective was used to visualize the cells. The images were processed by FIJI ImageJ 1.46j.

Replication Inhibition of the Enterovirus CVB3. Subconfluent monolayers of HeLa R19 cells were infected for 30 min at 37 °C with a *Renilla* luciferase-expressing Coxsackievirus B3 (RLuc-CVB3)⁴¹ at a multiplicity of infection (MOI) of 0.1 CCID₅₀ (50% cell culture infectious dose). After infection, the virus dilution was replaced by medium with 0.5, 5, or 50 μM of compound (from a 5 mM stock in DMSO) or the same amount of DMSO only as a negative control. After 7 h, the cells were processed either to measure the amount of luciferase produced as a measure for replication using a *Renilla* luciferase assay system (Promega, Madison (WI), USA), or for a viability assay using a CellTiter 96 Aqueous Non-Radioactive Cell Proliferation Assay (Promega, Madison (WI), USA). Triplicate measurements were normalized to the average of the negative control wells with the same DMSO dilution.

ASSOCIATED CONTENT

Supporting Information

Experimental details and analytical data for all compounds, determination of enantio- or diastereoselectivities for compounds **8**, **34**, and **35**, copies of ¹H NMR and ¹³C NMR spectra of all compounds, NCI 5-dose test results for compound **5**, X-ray crystal data for compounds **2**, **3**, **5**, **6**, **39a**, **42**, **48**, and **54**, cell viability during the replication inhibition of CVB3. This material is available free of charge via the Internet at <http://pubs.acs.org>.

Accession Codes

The Cambridge Crystallographic Data Center (CCDC) contains the supplementary crystallographic data for this paper in the Cambridge Structural Database (CSD). CCDC numbers: 925984 for compound **2**, 925985 for compound **3**, 925986 for compound **5**, 925987 for compound **6**, 925988 for compound **39a**, 925989 for compound **42**, 925990 for compound **48**, and 925991 for compound **54**.

AUTHOR INFORMATION

Corresponding Author

*Phone: +49-6221-548421. Fax: +49-6221-544205. E-mail: g.helmchen@oci.uni-heidelberg.de.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

This work was supported by the Deutsche Forschungsgemeinschaft (Graduiertenkolleg 850) and the Dr. Rainer Wild-Stiftung and grants from The Netherlands Organisation for Scientific Research (NWO) (an NWO-ALW open program grant and a VICI grant to F.v.K. and a VENI grant to J.S.). The authors thank Patrick Rieger for his kind assistance with cultivation of *Eupenicillium brefeldianum*. We thank the National Cancer Institute (NCI, U.S. National Institutes of Health,

Maryland, USA) for performing the anticancer screening within their Developmental Therapeutics Program (DTP).

■ ABBREVIATIONS USED

9-BBN, 9-borabicyclo[3.3.1]nonane; (–)-DBNE, (1S,2R)-(–)-2-(dibutylamino)-1-phenyl-1-propanol; DEAD, diethyl azodicarboxylate; DIAD, diisopropyl azodicarboxylate; dppf, 1,1'-bis(diphenylphosphino)ferrocene; KHMDS, potassium bis(trimethylsilyl)amide; MEM, methoxyethoxymethyl; NMO, 4-methylmorpholine N-oxide; TBAI, tetrabutylammonium iodide; TES, triisopropylsilyl; TBS, *tert*-butyldimethylsilyl

■ REFERENCES

- (1) In text, the common numbering for **1** is used (cf. Figures 1 and 2). This begins at the carbonyl group and continues anticlockwise around the molecule. In the Supporting Information, for identifying compound names and spectral data, IUPAC numbering is used.
- (2) Singleton, V. L.; Bohonos, N.; Ullstrup, A. J. Decumbin. A new compound from a species of *Penicillium*. *Nature* **1958**, *181*, 1072–1073.
- (3) (a) Sunagawa, M.; Ohta, T.; Nozoe, S. Biosynthesis of Brefeldin A. Introduction of Oxygen at the C-7 Position. *J. Antibiot.* **1983**, *36*, 25–29. (b) Yamamoto, Y.; Hori, A.; Hutchinson, C. R. Biosynthesis of Macrolide Antibiotics. 6. Late Steps in Brefeldin A Biosynthesis. *J. Am. Chem. Soc.* **1985**, *107*, 2471–2474.
- (4) Häri, E.; Loeffler, W.; Sigg, H. P.; Stähelin, H.; Tamm, C. Über die Isolierung neuer Stoffwechselprodukte aus *Penicillium brefeldianum* DODGE. *Helv. Chim. Acta* **1963**, *46*, 1235–1243.
- (5) Tamura, G.; Ando, K.; Suzuki, S.; Takatsuki, A.; Arima, K. Antiviral activity of Brefeldin A and Verrucarin A. *J. Antibiot.* **1968**, *21*, 160–161.
- (6) Bačiková, D.; Betina, V.; Nemec, P. Antinematodal activity of the antibiotic cyanein. *Naturwissenschaften* **1964**, *51*, 445.
- (7) Betina, V.; Montagnier, L. Action of cyanein on the synthesis of nucleic acids and proteins in animal cells and bacterial protoplasts. *Bull. Soc. Chim. Biol.* **1966**, *48*, 194–198.
- (8) (a) Betina, V.; Horáková, K.; Baráth, Z. Anti-HeLa cell effect of cyanein. *Naturwissenschaften* **1962**, *49*, 241. (b) DTP Data; Division of Cancer Treatment and Diagnostics, NCI/NIH; http://dtp.nci.nih.gov/docs/dtp_search.html (NSC for **1**, 56310; NSC for 15-nor-brefeldin A, 746708).
- (9) (a) Shao, R. G.; Shimizu, T.; Pommier, Y. Brefeldin A is a Potent Inducer of Apoptosis in Human Cancer Cells Independently of p53. *Exp. Cell Res.* **1996**, *227*, 190–196. (b) Nojiri, H.; Hori, H.; Nojima, S. Induction of Cell Differentiation and Apoptosis into Human Malignant Tumor Cell Lines by Drugs Affecting Ganglioside Biosynthesis. *Glycoconjugate J.* **1995**, *12*, 459. (c) Nojiri, H.; Many, H.; Isono, H.; Yamana, H.; Nojima, S. Induction of terminal differentiation and apoptosis in human colonic carcinoma cells by brefeldin A, a drug affecting ganglioside biosynthesis. *FEBS Lett.* **1999**, *453*, 140–144.
- (10) Activity of **1** in mammalian cells: (a) Fujiwara, T.; Oda, K.; Yokota, S.; Takatsuki, A.; Ikehara, Y. Brefeldin A Causes Disassembly of the Golgi Complex and Accumulation of Secretory Proteins in the Endoplasmic Reticulum. *J. Biol. Chem.* **1988**, *263*, 18545–18552. (b) Lippincott-Schwartz, J.; Yuan, L. C.; Bonifacino, J. S.; Klausner, R. D. Rapid Redistribution of Golgi Proteins into the ER in Cells Treated with Brefeldin A: Evidence for Membrane Cycling from Golgi to ER. *Cell* **1989**, *56*, 801–813. Activity of **1** in plant cells: (c) Nebenführ, A.; Madison, S. L. Live-Cell Imaging of Dual-Labeled Golgi Stacks in Tobacco BY-2 Cells Reveals Similar Behaviors for Different Cisternae during Movement and Brefeldin A Treatment. *Mol. Plant* **2011**, *4*, 896–908. (d) Nebenführ, A.; Ritzenthaler, C.; Robinson, D. G. Brefeldin A: Deciphering an Enigmatic Inhibitor of Secretion. *Plant Physiol.* **2002**, *130*, 1102–1108 and literature cited therein.
- (11) (a) Donaldson, J. G.; Finazzi, D.; Klausner, R. D. Brefeldin A inhibits Golgi membrane-catalysed exchange of guanine nucleotide onto ARF protein. *Nature* **1992**, *360*, 350–352. (b) Helms, J. B.; Rothman, J. E. Inhibition by brefeldin A of a Golgi membrane enzyme that catalyses exchange of guanine nucleotide bound to ARF. *Nature* **1992**, *360*, 350–352.
- (12) For the mechanism of vesicle budding and the function of G-proteins in this context see: (a) Rothman, J. E.; Wieland, F. T. Protein Sorting by Transport Vesicles. *Science* **1996**, *272*, 227–234. (b) Brügger, B.; Wieland, F. T. Mechanism der COPI-Vesikelbiogenese. *Biospektrum* **2004**, *1*, 30–33. (c) Bonifacino, J. S.; Lippincott-Schwartz, J. Coat proteins: shaping membrane transport. *Nature Rev. Mol. Cell Biol.* **2003**, *4*, 409–414.
- (13) Renault, L.; Guibert, B.; Cherfils, J. Structural snapshots of the mechanism and inhibition of a guanine nucleotide exchange factor. *Nature* **2003**, *426*, 525–530.
- (14) Mossessova, E.; Corpina, R. A.; Goldberg, J. Crystal Structure of ARF1-Sec7 Complexed with Brefeldin A and Its Implications for the Guanine Nucleotide Exchange Mechanism. *Mol. Cell* **2003**, *12*, 1403–1411.
- (15) Phillips, L. R.; Supko, J. G.; Malspeis, L. Analysis of Brefeldin A in Plasma by Gas Chromatography with Electron Capture Detection. *Anal. Biochem.* **1993**, *211*, 16–22.
- (16) For more information see: *Developmental Therapeutics Program*; Division of Cancer Treatment and Diagnostics, NCI/NIH; <http://dtp.nci.nih.gov>.
- (17) For brefeldin analogues derived from **1** see: (a) Zhu, J.-W.; Hori, H.; Nojiri, H.; Tsukuda, T.; Taira, Z. Synthesis And Activity Of Brefeldin A Analogs As Inducers Of Cancer Cell Differentiation And Apoptosis. *Bioorg. Med. Chem. Lett.* **1997**, *7*, 139–144. (b) Argade, A. B.; Devraj, R.; Vroman, J. A.; Haugwitz, R. D.; Hollingshead, M.; Cushman, M. Design and Synthesis of Brefeldin A Sulfide Derivatives as Prodrug Candidates with Enhanced Aqueous Solubilities. *J. Med. Chem.* **1998**, *41*, 3337–3346. (c) Argade, A. B.; Haugwitz, R. D.; Devraj, R.; Kozlowski, J.; Fanwick, P. E.; Cushman, M. Highly Efficient Diastereoselective Michael Addition of Various Thiols to (+)-Brefeldin A. *J. Org. Chem.* **1998**, *63*, 273–278. (d) Fox, B. M.; Vroman, J. A.; Fanwick, P. E.; Cushman, M. Preparation and Evaluation of Sulfide Derivatives of the Antibiotic Brefeldin A as Potential Prodrug Candidates with Enhanced Aqueous Solubilities. *J. Med. Chem.* **2001**, *44*, 3915–3924. (e) Anadu, N. O.; Davison, V. J.; Cushman, M. Synthesis and Anticancer Activity of Brefeldin A Ester Derivatives. *J. Med. Chem.* **2006**, *49*, 3897–3905. (f) Ref 17g. For brefeldin analogues derived by total synthesis see: (g) Förster, S.; Persch, E.; Tverskoy, O.; Rominger, F.; Helmchen, G.; Klein, C.; Gönen, B.; Brügger, B. Syntheses and Biological Properties of Brefeldin Analogues. *Eur. J. Org. Chem.* **2011**, 878–891. (h) Hübscher, T.; Helmchen, G. Enantioselective Formal Synthesis of Brefeldin A and Analogues via Anionic Cyclization of an Alkenyl Epoxide. *Synlett* **2006**, 1323–1326. (i) Förster, S.; Helmchen, G. Stereoselective Synthesis of a Lactam Analogue of Brefeldin C. *Synlett* **2008**, 831–836. (j) Paek, S.-M.; Seo, S.-Y.; Min, K.-H.; Shin, D. M.; Chung, Y. K.; Suh, Y.-G. Synthesis of Lactam Analogue of 4-epi-Brefeldin A. *Heterocycles* **2007**, *71*, 1059–1066. (k) Gao, J.; Huang, Y.-X.; Wu, Y. Enantioselective total synthesis of 13-O-brefeldin A. *Tetrahedron* **2008**, *64*, 11105–11109. (l) Archambaud, S.; Aphecetche-Julienne, K.; Guingant, A. A New Total Synthesis of (+)-Brefeldin C. *Synlett* **2005**, 139–143. (m) Archambaud, S.; Legrand, F.; Aphecetche-Julienne, K.; Collet, S.; Guingant, A.; Evain, M. Total Synthesis of (+)-Brefeldin C, (+)-nor-Me Brefeldin A and (+)-4-epi-nor-Me Brefeldin A. *Eur. J. Org. Chem.* **2010**, 1364–1380. (n) Inai, M.; Nishii, T.; Mukoujima, S.; Esumi, T.; Kaku, H.; Tominaga, K.; Abe, H.; Horikawa, M.; Tsunoda, T. Total Synthesis of (+)-Brefeldin C Utilizing Aza-Claisen Rearrangement. *Synlett* **2011**, 1459–1461.
- (18) Kozikowski, A. P.; Shum, P. W.; Basu, A.; Lazo, J. S. Synthesis of structural analogues of lyngbyatoxin A and their evaluation as activators of protein kinase C. *J. Med. Chem.* **1991**, *34*, 2420–2430.
- (19) Reviews: (a) Soai, K.; Niwa, S. Enantioselective Addition of Organozinc Reagents to Aldehydes. *Chem. Rev.* **1992**, *92*, 833–856. (b) Pu, L.; Yu, H.-B. Catalytic Asymmetric Organozinc Additions to Carbonyl Compounds. *Chem. Rev.* **2001**, *101*, 757–824.

- (20) Soai, K.; Yokoyama, S.; Ebihara, K.; Hayasaka, T. A New Chiral Catalyst for the Highly Enantioselective Addition of Dialkylzinc Reagents to Aliphatic Aldehydes. *J. Chem. Soc., Chem. Commun.* **1987**, 1690–1691.
- (21) Blakemore, P. R.; Kocienski, P. J.; Marczak, S.; Wicha, J. The Modified Julia Olefination in Vitamin D₂ Synthesis. *Synthesis* **1999**, 1209–1215.
- (22) For syntheses of **24** not starting from **1** see: Haynes, R. K.; Lam, W. W.-L.; Yeung, L.-L.; Williams, I. D.; Ridley, A. C.; Starling, S. M.; Vonwiller, S. C.; Hambley, T. W.; Lelandais, P. Highly diastereoselective conjugate addition of lithiated γ -crotonolactone (but-2-en-4-olide) to cyclic enones to give syn-adducts: application to a brefeldin synthesis. *J. Org. Chem.* **1997**, 62, 4552–4553.
- (23) Trost, B. M.; Crawley, M. L. A “chiral aldehyde” equivalent as a building block towards biologically active targets. *Chem.—Eur. J.* **2004**, 10, 2237–2252. This article also contains an extensive bibliography on previous total syntheses of **1**.
- (24) Inanaga, J.; Hirata, K.; Saeki, H.; Katsuki, T.; Yamaguchi, M. A rapid esterification by means of mixed anhydride and its application to large-ring lactonization. *Bull. Chem. Soc. Jpn.* **1979**, 52, 1989–1993.
- (25) Williams, D. R.; Jass, P. A.; Tse, H.-L. A.; Gaston, R. D. Total Synthesis of (+)-breyndolide. *J. Am. Chem. Soc.* **1990**, 112, 4552.
- (26) Reviews: (a) Müller, K.; Faeh, C.; Diederich, F. Fluorine in pharmaceuticals: looking beyond intuition. *Science* **2007**, 317, 1881–1886. (b) Purser, S.; Moore, P. R.; Swallow, S.; Gouverneur, V. Fluorine in medicinal chemistry. *Chem. Soc. Rev.* **2008**, 37, 320–330. (c) O'Hagan, D. Understanding organofluorine chemistry. An introduction to the C–F bond. *Chem. Soc. Rev.* **2008**, 37, 308–319.
- (27) (a) Ruppert, I.; Schlich, K.; Volbach, W. Die ersten CF₃-substituierten Organyl(chlor)silane. *Tetrahedron Lett.* **1984**, 25, 2195–2198. (b) Prakash, G. K. S.; Krishnamurti, R.; Olah, G. A. Fluoride-induced trifluoromethylation of carbonyl compounds with trifluoromethyltrimethylsilane (TMS-CF₃). A trifluoromethide equivalent. *J. Am. Chem. Soc.* **1989**, 111, 393–395.
- (28) (a) Gärtner, M.; Mader, S.; Seehafer, K.; Helmchen, G. Enantio- and regioselective iridium-catalyzed allylic hydroxylation. *J. Am. Chem. Soc.* **2011**, 133, 2072–2075. (b) Spiess, S.; Welter, C.; Franck, G.; Taquet, J.-P.; Helmchen, G. Iridium-catalyzed asymmetric allylic substitutions—very high regioselectivity and air stability with a catalyst derived from dibenzo[a,e]cyclooctatetraene and a phosphoramidite. *Angew. Chem., Int. Ed.* **2008**, 47, 7652–7655. (c) Raskatov, J. A.; Spiess, S.; Gnam, C.; Brödner, K.; Rominger, F.; Helmchen, G. Ir-catalyzed asymmetric allylic substitutions with cyclometalated (phosphoramidite)Ir complexes—resting states, catalytically active (π -allyl)Ir complexes and computational exploration. *Chem.—Eur. J.* **2010**, 16, 6601–6615.
- (29) Reviews: (a) Kolb, H. C.; VanNieuwenhze, M. S.; Sharpless, K. B. Catalytic asymmetric dihydroxylation. *Chem. Rev.* **1994**, 94, 2483–2547. (b) Lohray, B. B. Recent advances in the asymmetric dihydroxylation of alkenes. *Tetrahedron: Asymmetry* **1992**, 3, 1317–1349.
- (30) Sharpless, K. B.; Amberg, W.; Bennani, Y. L.; Crispino, G. A.; Hartung, J.; Jeong, K.-S.; Kwong, H.-L.; Morikawa, K.; Wang, Z.-M.; Xu, D.; Zhang, X.-L. The osmium-catalyzed asymmetric dihydroxylation: a new ligand class and a process improvement. *J. Org. Chem.* **1992**, 57, 2768–2771.
- (31) Greene, A. E.; Le Drian, C.; Crabbé, P. An efficient total synthesis of ($\pm$)-Brefeldin-A. *J. Am. Chem. Soc.* **1980**, 102, 7583–7584.
- (32) Review: Tsuji, J. Synthetic applications of the palladium-catalyzed oxidation of olefins to ketones. *Synthesis* **1984**, 5, 369–384.
- (33) Internal ID numbers of the NCI (NSC) for compounds not listed in Table 2: 4 (NSC763496), 42 (NSC761153), 43 (NSC761155), 54 (NSC757950), (6R)-hydroxybrefeldin A (NSC751150), (7S)-aminobrefeldin C (NSC671437), lactam analogue of **1** (NSC652682).
- (34) Langhans, M.; Förster, S.; Helmchen, G.; Robinson, D. G. Differential effects of the brefeldin A analogue (6R)-hydroxy-brefeldin A in tobacco and Arabidopsis. *J. Exp. Bot.* **2011**, 62, 2949–2957.
- (35) Irurzun, A.; Perez, L.; Carrasco, L. Involvement of membrane traffic in the replication of poliovirus genomes: effects of brefeldin A. *Virology* **1992**, 191, 166–175.
- (36) Maynell, L. A.; Kirkegaard, K.; Klymkowsky, M. W. Inhibition of Poliovirus RNA Synthesis by Brefeldin A. *J. Virol.* **1992**, 66, 1985–1994.
- (37) Hsu, N.-Y.; Ilnytska, O.; Belov, G.; Santiana, M.; Chen, Y.-H.; Takvorian, P. M.; Pau, C.; van der Schaar, H.; Kaushik-Basu, N.; Balla, T.; Cameron, C. E.; Ehrenfeld, E.; van Kuppeveld, F. J. M.; Altan-Bonnet, N. Viral Reorganization of the Secretory Pathway Generates Distinct Organelles for RNA Replication. *Cell* **2010**, 141, 799–811.
- (38) Nagy, P. D.; Pogany, J. The dependence of viral RNA replication on co-opted host factors. *Nature Rev. Microbiol.* **2011**, 10, 137–149.
- (39) Wessels, E.; Duijsings, D.; Niu, T.-K.; Neumann, S.; Oorschot, V. M.; de Lange, F.; Lanke, K. H. W.; Klumperman, J.; Henke, A.; Jackson, C. L.; Melchers, W. J. G.; van Kuppeveld, F. J. M. A Viral Protein that Blocks Arf1-Mediated COP-I Assembly by Inhibiting the Guanine Nucleotide Exchange Factor GBF1. *Dev. Cell* **2006**, 11, 191–201.
- (40) Belov, G. A.; Altan-Bonnet, N.; Kovtunovych, G.; Jackson, C. L.; Lippincott-Schwartz, J.; Ehrenfeld, E. Hijacking Components of the Cellular Secretory Pathway for Replication of Poliovirus RNA. *J. Virol.* **2007**, 81, 558–567.
- (41) Lanke, K. H. W.; van der Schaar, H. M.; Belov, G. A.; Feng, Q.; Duijsings, D.; Jackson, C. L.; Ehrenfeld, E.; van Kuppeveld, F. J. M. GBF1, a Guanine Nucleotide Exchange Factor for Arf, Is Crucial for Cocksackievirus B3 RNA Replication. *J. Virol.* **2009**, 83, 11940–11949.
- (42) Mansour, S. J.; Skaug, J.; Zhao, X.-H.; Giordano, J.; Scherer, S. W.; Melançon, P. p200 ARF-GEP1: a Golgi-localized guanine nucleotide exchange protein whose Sec7 domain is targeted by the drug brefeldin A. *Proc. Natl. Acad. Sci. U. S. A.* **1999**, 96, 7968–7973.
- (43) Peyroche, A.; Antonny, B.; Robineau, S.; Acker, J.; Cherfils, J.; Jackson, C. L. Brefeldin A Acts to Stabilize an Abortive ARF-GDP-Sec7 Domain Protein Complex: Involvement of Specific Residues of the Sec7 Domain. *Mol. Cell* **1999**, 3, 275–285.
- (44) MacroModel is a product of Schrödinger, LLC; for detailed information see: MacroModel; Schrödinger, LLC: New York, 2013; <http://www.schrodinger.com/products/14/11>.
- (45) (a) Chang, G.; Guida, W. C.; Still, W. C. An Internal Coordinate Monte Carlo Method for Searching Conformational Space. *J. Am. Chem. Soc.* **1989**, 111, 4379–4386. (b) Method details: mmffs, energy minimization by a conjugate gradient method (PRCG), Monte Carlo Multiple Minimum (MCM) conformational search using the implemented automatic setup, H₂O was used as solvent model.
- (46) (a) Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and Validation of a Genetic Algorithm for Flexible Docking. *J. Mol. Biol.* **1997**, 267, 727–748. (b) For more information see: GOLD 5.1; Cambridge Crystallographic Data Centre: Cambridge, UK; http://www.ccdc.cam.ac.uk/products/life_sciences/gold.
- (47) (a) Pettersen, E. F.; Goddard, T. D.; Huang, C. C.; Couch, G. S.; Greenblatt, D. M.; Meng, E. C.; Ferrin, T. E. UCSF Chimera—A Visualization System for Exploratory Research and Analysis. *J. Comput. Chem.* **2004**, 25, 1605–1612. (b) For more information see: UCSF Chimera, An Extensible Molecular Modeling System; University of California, San Francisco: San Francisco, CA; <http://www.cgl.ucsf.edu/chimera>.
- (48) Biological Macromolecular Resource; RCSB Protein Data Bank; <http://www.rcsb.org/pdb/home/home.do>.
- (49) Dettmer, J.; Hong-Hermesdorf, A.; Stierhof, Y.-D.; Schumacher, K. Vacuolar H⁺-ATPase Activity Is Required for Endocytic and Secretory Trafficking in Arabidopsis. *Plant Cell* **2006**, 18, 715–730.
- (50) Murashige, T.; Skoog, F. A. A Revised Medium for Rapid Growth and Bio Assays with Tobacco Tissue Cultures. *Physiol. Plant.* **1962**, 15, 473–497.
- (51) Rutz, C.; Satoh, A.; Ronchi, P.; Brügger, B.; Warren, G.; Wieland, F. T. Following the Fate In Vivo of COPI Vesicles Generated In Vitro. *Traffic* **2009**, 10, 994–1005.